CSPC Pharmaceutical (HKG:1093) obtained marketing approval for its iron sucrose injection from China's National Medical Products Administration.
The product is indicated for patients with iron deficiency anemia who don't respond satisfactorily to oral iron preparations, according to a Thursday filing.